This research develops small-molecule treatments for chikungunya virus using a lock-and-key approach targeting viral proteins. A key challenge—molecular orientation (enantiomers)—was addressed with a new synthesis method producing over 95% effective molecules. The optimized compound, BDGR-651, shows promise as a future antiviral treatment for this debilitating disease.

This research examines how combined THC and alcohol use alters neural communication and increases alcohol consumption. Using animal models, the study shows that co-use disrupts the glutamate system, heightening motivation to drink. Regulating glutamate with the compound CDPPB reduces alcohol intake, highlighting glutamate as a promising therapeutic target for addictio

Presbyopia, the age-related loss of near vision, occurs when the eye’s crystalline lens stiffens. A known lens-softening drug, Bistatin, affects too many eye structures to be safe. This research creates a targeted antibody–drug conjugate that delivers Bistatin only to the lens, restoring flexibility and offering a potential non-surgical treatment.

This research tests the safety of a new hypertension drug designed for patients who don’t respond to current medications. Through four phases of pre-clinical toxicology studies in cells and mice, the drug showed no major toxicity and effectively lowered blood pressure, supporting its progression toward future human clinical trials.